Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 11/20 | 0.55 |
| ▸ | CHRM3 | P20309 | 11/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.54 |
| ▸ | HRH1 | P35367 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.49 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.49 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.45 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bevonium SCHEMBL1650540 | 0.96 | CHRM2 (0.51) | CHRM2CHRM3CYP2D6KCNH2LMNA | |
| Poldine SCHEMBL250977 | 0.92 | CHRM2 (0.48) | CHRM2CHRM3CYP2D6KCNH2LMNA | |
| Bevonium SCHEMBL28086190 | 0.91 | CHRM2 (0.47) | CHRM2CHRM3CYP2D6KCNH2LMNA | |
| Bevonium SCHEMBL28439272 | 0.90 | CHRM2 (0.46) | CHRM2CHRM3CYP2D6KCNH2LMNA | |
| Bevonium SCHEMBL25016 | 0.89 | CHRM2 (0.45) | CHRM2CHRM3CYP2D6KCNH2LMNA | |
| Oxypyrronium SCHEMBL29388831 | 0.84 | POLB (0.57) | CHRM2CHRM3CYP2D6KCNH2LMNA | |
| Oxypyrronium SCHEMBL916858 | 0.83 | CHRM2 (0.56) | CHRM2CHRM3CYP2D6KCNH2LMNA | |
| Poldine SCHEMBL28086707 | 0.83 | CHRM2 (0.67) | CHRM2CHRM3CYP2D6KCNH2LMNA | |
| SCHEMBL1087914 | 0.81 | CHRM2 (0.47) | CHRM2CHRM3CYP2D6KCNH2LMNA | |
| SCHEMBL1087915 | 0.81 | CHRM2 (0.47) | CHRM2CHRM3CYP2D6KCNH2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 359 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4154879-B1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NICOTINE WITHDRAWAL SYMPTOMS | KOREA INST SCI & TECH (KR) | 2025-09-10 | — | — | EP | claimed |
| EP-4154879-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NICOTINE WITHDRAWAL SYMPTOMS | Korea Institute of Science and Technology (KR) | 2023-03-29 | — | — | EP | claimed |
| US-11065205-B2 | Immediate/delayed drug delivery | DRUG DELIVERY INTERNATIONAL LIMITED (GB) | 2021-07-20 | — | — | US | claimed |
| US-10689370-B2 | Cyclopropane carboxamide modulators of cystic fibrosis transmembrane conductance regulator | AUSPEX PHARMACEUTICALS, INC. (US) | 2020-06-23 | — | — | US | claimed |
| US-20190125679-A1 | IMMEDIATE/DELAYED DRUG DELIVERY | UNIVERSITY OF STRATHCLYDE (GB) | 2019-05-02 | — | — | US | claimed |
| EP-3373943-A1 | CONTROL OF CELLULAR REDOX LEVELS | Mckenna, Elizabeth (US) | 2018-09-19 | — | — | EP | claimed |
| CN-108430482-A | Control of cellular redox levels | 伊丽莎白·麦克纳 | 2018-08-21 | — | — | CN | claimed |
| EP-2956450-B1 | HYDROXYINDALPINE DERIVATIVES AND THEIR MEDICAL USE | UNIV MUENCHEN TECH (DE) | 2018-07-25 | — | — | EP | claimed |
| EP-2542228-B1 | PULSATILE DRUG RELEASE | UNIV STRATHCLYDE (GB) | 2017-11-29 | — | — | EP | claimed |
| EP-2542226-B1 | DELAYED PROLONGED DRUG DELIVERY | UNIV STRATHCLYDE (GB) | 2017-11-22 | — | — | EP | claimed |
| WO-2008059190-A1 | TREATMENT OF EXCESS SEBUM PRODUCTION | SUMMIT (CAMBRIDGE) LIMITED (GB) | 2008-05-22 | — | — | WO | claimed |
| WO-2007141530-A2 | TREATMENT OF EXCESS SEBUM PRODUCTION | SUMMIT (CAMBRIDGE) LIMITED (GB) | 2007-12-13 | — | — | WO | claimed |
| WO-2007135574-A1 | USE OF PARASYMPATHOLYTIC SUBSTANCES TO ENHANCE AND ACCELERATE STEM CELL DIFFERENTIATION, RELATED METHOD AND COMPOSITIONS | UNIVERSITA' DEGLI STUDI DI TORINO (IT) | 2007-11-29 | — | — | WO | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| EP-1273301-B1 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON SA (CH) | 2006-09-06 | — | — | EP | claimed |
| EP-1202723-A2 | USE OF ANTI-MUSCARINIC AGENTS FOR TREATING SKIN DISORDERS | Arakis Limited (GB) | 2002-05-08 | — | — | EP | claimed |
| WO-2001010427-A2 | USE OF ANTI-MUSCARINIC AGENTS FOR TREATING SKIN DISORDERS | ARAKIS LIMITED (GB) | 2001-02-15 | — | — | WO | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10689370-B2 | Cyclopropane carboxamide modulators of cystic fibrosis transmembrane conductance regulator | CFTR, CLCN2, TMEM120A | CHRM2 1950/4885CHRM3 748/4885CYP2D6 4330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.